STAT+: Sellas’ experimental blood cancer immunotherapy reduced risk of death in clinical trial

Sellas' experimental blood cancer immunotherapy reduced the risk of death in clinical trial.
This is a brief. The reporting belongs to STAT — read the complete story, with full context and credits, at the source.
Read the full story at STAT ↗statnews.com
More from the Health desk

STAT+: With $173 million, new startup takes aim at sickle cell

I'm a human doctor with human intelligence. But I sure do like my AI notetaker

More people are getting the flu. Should you get a flu shot before you travel?

Luas disruption following ‘medical emergency’ on Dublin city centre tram

STAT+: After death in gene therapy trial for a brain disease, progress is reported
